I propose that healthy aging triggers an "adaptive decoupling" of the amygdala by progressively downregulating CREB expression in central amygdala (CeA) CRF neurons. This mechanism functions as a circuit-level "circuit breaker" that blocks fear-memory consolidation. In preclinical Alzheimer’s Disease (AD), however, focal tau accumulation in the CeA disrupts this program, inducing a compensatory, aberrant upregulation of the Orexin-1 receptor (OX1R) signaling cascade. Instead of being quieted, the aging amygdala becomes hyper-sensitized to hypothalamic orexinergic tone, preventing the extinction learning that typically underpins the "positivity effect" of healthy aging [https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1033543/full].

In healthy aging, the reduced fractional anisotropy between the amygdala and ventral PFC [https://pmc.ncbi.nlm.nih.gov/articles/PMC4087066/] should theoretically cause anxiety. The resilience we observe suggests a compensatory mechanism at play. I argue that the age-related drop in CREB signaling within CeA CRF neurons [https://ouci.dntb.gov.ua/en/works/lxadjrV9/] isn't just a loss of function; it’s a programmed downregulation that prevents fear-memory encoding, effectively "pruning" the amygdala’s emotional output.

In the pathological aging phenotype, tau aggregation likely interferes with the proteostatic clearance of transcription factors [https://pmc.ncbi.nlm.nih.gov/articles/PMC4087066/]. My hypothesis suggests that tau-induced microglial inflammation triggers an IL-6/TNF-α feedback loop, which reinforces p38 MAPK-mediated CREB stabilization. At the same time, this inflammatory environment drives OX1R upregulation in the CeA. As a result, the amygdala shifts from a healthy "disconnected" state to being "hyper-coupled" to the orexin system. This forces the amygdala to encode threats even when no salient cues are present, which may explain the shift from healthy emotional aging to late-life generalized anxiety.

To test this, I suggest three approaches:

1. Longitudinal Mapping: Use PET imaging to track [18F]Flortaucipir uptake in the medial amygdala alongside orexin-antagonist sensitivity in aging cohorts. If the hypothesis is correct, patients with a high tau burden should show a significant reduction in anxiety after taking dual orexin receptor antagonists (DORAs), while healthy older adults should remain largely unaffected.
2. Molecular Validation: Use Cre-dependent viral tracing in tau-transgenic mouse models to selectively knockdown CREB in CeA-CRF neurons. If the "adaptive decoupling" theory holds, restoring CREB in these mice should reverse the anxiety phenotype.
3. Falsification: If orexin antagonism doesn’t modulate anxiety in tau-positive cohorts, the idea that orexinergic hypersensitivity is the primary driver of late-life pathological anxiety—as opposed to intrinsic circuit degradation—will be falsified.

This framework suggests that late-life anxiety acts as a biomarker for "failed pruning" of the fear circuit. The therapeutic potential, therefore, likely lies not in broad-spectrum anxiolytics, but in targeted inhibition of the CeA-Orexin-CREB signaling axis.